Secondary Study Conducted To Identify 3-Bromopyruvate Protein-Targets
Bioorthogonal Profiling of a Cancer Cell Proteome Identifies a Large Set of 3‑Bromopyruvate Targets beyond Glycolysis
Authors: Narek Darabedian1, Thomas C. Chen2, Henrik Molina3, Matthew R. Pratt1, Axel H. Schönthal, PhD3, and Axel H. Schönthal2
In its initial study on the effects of 3-Bromopyruvate (3BP) in conjunction with Peryllil Alcohol to impact tumor cell growth by inhibiting glyceraldehyde 3-phosphate dehydrogenase (GAPDH) production resulting in energy depletion in the tumor cell, NeOnc Technologies was able to demonstrate that it’s NEO 218 formulation had a significantly higher impact on lowering GAPDH production. The study also showed that 3BP was also creating an addition of excess pyruvate, the final product of glycolysis, indicating that GAPDH may not be the only relevant target of 3BP and that modification of cysteine residues may be occurring in many different proteins.
This secondary study was conducted to directly test this hypothesis in order to determine what additional target proteins may be targeted by 3BP. Identification of these other targets will lead to a better understanding of 3BP’s ability to slow tumor cell growth, and to help eliminate any adverse secondary issues relating to this treatment protocol.